Estrogen signaling in the ovary is a fundamental component of normal ovarian function, and evidence also indicates that excessive estrogen is a risk factor for ovarian cancer. We have previously demonstrated that the gonadally enriched TFIID subunit TAF4B, a paralog of the general transcription factor TAF4A, is required for fertility in mice and for the proliferation of ovarian granulosa cells following hormonal stimulation. However, the relationship between TAF4B and estrogen signaling in the normal ovary or during ovarian tumor initiation and progression has yet to be defined. Herein, we show that Taf4b mRNA and TAF4B protein, but not Taf4a mRNA or TAF4A protein, are increased in whole ovaries and granulosa cells of the ovary after exposure to 17beta-estradiol or the synthetic estrogen diethylstilbestrol and that this response occurs within hours after stimulation. Furthermore, this increase occurs via nuclear estrogen receptors both in vivo and in a mouse granulosa cancer cell line, NT-1. We observe a significant increase in Taf4b mRNA in estrogen-supplemented mouse ovarian tumors, which correlates with diminished survival of these mice. These data highlight the novel response of the general transcription factor TAF4B to estrogen in the normal ovary and during ovarian tumor progression in the mouse, suggesting its potential role in regulating actions downstream of estrogen stimulation.
INTRODUCTION
Normal ovarian functions, including processes of its own development, folliculogenesis, and ovulation, are governed by hormonal signals from estrogen, progesterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH). Epidemiological and experimental studies support the idea that disruption of these carefully controlled pathways can contribute to disease states, including infertility [1, 2] and ovarian cancer [3] . Female infertility affects approximately 10.9% of women aged 15 to 44 yr in the United States [4] , and the molecular mechanisms leading to this disorder are multifaceted and varied. Conditions associated with infertility or subfertility include endometriosis, polycystic ovarian syndrome, and premature ovarian failure (POF). A hallmark of all of these disorders is deregulated hormone levels [5] [6] [7] . Consistent with an endocrine component of these diseases, investigations have identified endocrine-disrupting chemicals as a risk factor for the development of these conditions [2] . However, our understanding of the molecular mechanisms contributing to disorders of impaired ovarian function is largely insufficient.
Experimental studies have also implicated estrogens and xenoestrogens in the modulation of ovarian cancer cell proliferation in vitro [8] [9] [10] and in vivo [11] . In particular, transgenic mice expressing simian virus 40 T antigen in the ovarian surface epithelium (OSE) via a Cre recombinase-locus of X-over P1-inducible system (tgCAG-LS-TAg mice) demonstrated more rapid onset of tumor development, altered histological appearance, and diminished survival when exposed to 17b-estradiol throughout tumorigenesis [12] . Corroborating the importance of these experimental results, multiple epidemiological studies [13] [14] [15] [16] [17] [18] have demonstrated that longterm use of estrogen-only hormone replacement therapy increases a woman's risk of ovarian cancer. Together, these findings support the notion that estrogen may have a key role in ovarian cancer initiation or progression in women. However, the underlying molecular mechanisms responsible for this effect are still unknown and may include both direct cellular effects and effects on the tumor microenvironment.
Estrogen signaling is a carefully balanced and integrated component of proper ovarian functions. 17b-Estradiol is the most abundant and potent form of endogenous estrogen and is produced by granulosa cells of the ovary [19, 20] . It has a critical role in regulation of folliculogenesis by stimulating granulosa cell proliferation and enabling the actions of FSH and LH. In turn, FSH stimulates the conversion of androgens to estrogens, and the increased proliferation of granulosa cells prompted by estrogen leads to further estrogen production [19] . Classical genomic estrogen receptor (ER) signaling begins with the binding of estrogen to the nuclear receptors ERa or ERb. The ligand-bound receptors then homodimerize or heterodimerize and activate transcription by binding to estrogenresponse elements (EREs) in target gene promoters [20, 21] . On the other hand, nonclassical genomic ER signaling can occur by way of ER interactions with other transcription factors at non-ERE sites [21] . Estrogen-response genes have been extensively characterized in breast cancer cell lines [22] , but little research has been done in ovarian tissue or cell lines. Elucidating ER targets in normal and transformed ovarian tissue in vivo is essential to broaden our understanding of how estrogen signaling contributes to both normal ovarian function and ovarian tumorigenesis.
Two recent genomic studies have linked the gonadally enriched TFIID subunit TAF4B with human infertility and ovarian cancer. A genome-wide association study [23] found a significant association between single-nucleotide polymorphisms in TAF4B and human POF, and a bioinformatics study [24] revealed that the TFIID complex is a significantly altered subnetwork in ovarian cancer, with Taf4b gene amplifications or mRNA upregulation occurring in a subset of these tumors [25] . Prior research in our laboratory has uncovered the crucial tissue-specific role of TAF4B in murine fertility [26] . We have previously shown that Taf4b-null females are completely infertile due to multiple defects resembling POF [27, 28] . Importantly, despite the presence of normal levels of receptors for FSH and estrogen in Taf4b-null mice at 3 wk of age, granulosa cells in immature Taf4b-null ovaries fail to respond properly to proliferative signals from equine chorionic gonadotropin (eCG) or 17b-estradiol [28] , prompting us to hypothesize that TAF4B is involved in a hormonal signaling pathway in the ovary. To elucidate if there is a link between estrogen signaling and TAF4B function in the ovary, we first set out to determine if TAF4B expression is increased during hormonal proliferative responses in normal mouse ovaries and ovarian tumors. The results presented herein will set the foundation for further research to elucidate if TAF4B has a role in the execution of estrogen-dependent effects in the mouse ovary, as well as the impact this regulation has on ovarian health and disease in women.
MATERIALS AND METHODS

Animals
All animal protocols using C57Bl/6 mice (Jackson Laboratories) were performed at Brown University. Mice were killed by carbon dioxide euthanasia, and all animal protocols performed at Brown University were reviewed and approved by the Brown University Institutional Animal Care and Use Committee and were performed in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals. Protocols utilizing Ex3-ERKO mice were performed at the National Institute of Environmental Health Sciences and were approved by the NIH Animal Care and Use Committee. All animal protocols utilizing tgCAG-LS-TAg and severe combined immunodeficiency (SCID) mice were carried out at the University of Ottawa. Mice were killed by carbon dioxide euthanasia, and protocols were performed according to the Guidelines for the Care and Use of Animals established by the Canadian Council on Animal Care. Animal studies performed at all institutes met the criteria set forth by the Society for the Study of Reproduction for the care and use of experimental animals.
17a-Estradiol, 17b-Estradiol, Diethylstilbestrol, and eCG In Vivo Treatments
Four-week-old C57Bl/6 mice were used for all experiments. For the doseresponse experiments, mice were injected s.c. with 0.25 to 2.0 mg of 17b-estradiol (E8875; Sigma) dissolved in corn oil or with corn oil alone, once daily for 3 days, and were killed on the fourth day (n ¼ 3 per dose). Similarly, mice were injected s.c. with 1.0 mg of 17b-estradiol (E8875; Sigma), 17a-estradiol (E8750; Sigma), or diethylstilbestrol (DES) (D4628; Sigma) dissolved in corn oil or with corn oil alone, once daily for 3 days, and were killed on the fourth day (n ¼ 3-4 per treatment group). Mice treated for the time course were injected once i.p. with 1.0 mg/kg of DES dissolved in ethanol and then diluted in corn oil. Control mice received 100 ll of corn oil with 14% ethanol. Mice were killed at 0, 1, 3, 6, and 24 h after treatment (n ¼ 3 per treatment group per time point). For the antagonist experiments, mice were injected i.p. with 20 mg/ kg of ICI 182 780 (I4409; Sigma) or with vehicle alone (100 ll of corn oil with 14% ethanol), and then half of the antagonist-treated mice were treated i.p. with 0.5 mg/kg of DES 1 h later. These mice were killed 4 h after the DES injection (n ¼ 3 per treatment group). This protocol was adapted from a published protocol for in vivo ICI 182 780 treatment [29] 
Estrogen-Supplemented Ovarian Tumor Progression
A mouse ovarian cancer cell line was established from the ascites of tumorigenic estradiol-treated tgCAG-LS-TAg mice [12] and was tested for tumorigenicity by i.p. injections of 10 million ascites cells into Fox Chase ovariectomized SCID mice (Charles River). At the time of injection, SCID mice concurrently received a 60-day slow-release 17b-estradiol pellet (0.25 mg; n ¼ 4; SE-121; Innovative Research of America) or placebo pellet (n ¼ 6; SC-111; Innovative Research of America) placed s.c. in the neck. Mice were killed at first signs of morbidity (characterized by weight loss .15% of body weight, body weight increase .5 g with respect to nontumorigenic age-matched controls, abdominal distension impairing mobility, respiratory distress, dehydration, anorexia, and/or diarrhea). Total RNA from a representative sample of tumor tissue was collected using an RNeasy Mini Kit (74104; Qiagen).
Purified Granulosa Cell Isolation
C57Bl/6 mice were injected s.c. with DES or corn oil alone once daily for 3 days or with eCG or saline once i.p. as described above. Granulosa cell isolation was performed as previously described [28] . Purified granulosa cell suspension was pooled from three mice (DES experiments) and five mice (eCG experiments) per sample, spun down and washed twice with sterile PBS, and then resuspended in 0.2 M potassium chloride extraction buffer to collect protein or in Trizol for total RNA isolation (n ¼ 3 sets of pooled granulosa cells per treatment group for the DES experiments; n ¼ 1 set of pooled granulosa cells for the eCG experiments). RNA and protein were collected during two separate experiments for both DES and eCG treatment.
Cell Culture and Transfection
NT-1 cells are a well-characterized mouse granulosa cancer cell line [31] . For the overexpression studies, NT-1 cells (passage 23) were plated at 400 000 cells per well in six-well plates (n ¼ 6) in Dulbecco modified Eagle medium (D5796; Sigma), with 10% fetal bovine serum and 1% penicillin-streptomycin. Twenty-four hours later, cells were transfected with 2 lg per well of either 33FLAG-ERb (mouse Esr2 cloned into pCMV10-33FLAG; E7658; Sigma) or empty vector, using FuGENE HD Transfection Reagent (E2311/2; Promega) at a FuGENE:DNA ratio of 3:1. Forty-eight hours later, cells were harvested for total RNA by Trizol extraction/lithium chloride precipitation and protein by 0.2 M potassium chloride extraction. Quantitative RT-PCR was performed to assess levels of Taf4a and Taf4b mRNA, and whole-cell lysate was analyzed for expression of TAF4A, TAF4B, 33FLAG-ERb, and b-tubulin by Western blot. Cloning of 33FLAG-ERb was performed by amplifying Esr2 from wholemouse ovary cDNA made using an iScript Select cDNA Synthesis Kit (170-WARDELL ET AL.
8896; Bio-Rad). The following primers were used: F -AAACAGAGA GACCCTGAAGAGAA and R -CCTCTTGGCGCTTGGACTAG. The product was then ligated into the pCMV10-33FLAG vector.
Quantitative RT-PCR and Statistical Analysis
Whole ovaries were collected from 3-mo-old Ex3aERKO (n ¼ 3) [32] , Ex3bERKO (n ¼ 4) [33] , and Ex3abERKO (n ¼ 4) [34] mice and control mice (n ¼ 4), which were either wild type or heterozygous for ERa, ERb, or both. In order to use littermates for the study, control mice were utilized as opposed to pure wild-type mice because only 1 in 32 mice would be expected to be pure wild types. Whole ovaries or granulosa cells were also collected from treated animals, and total RNA was extracted by Trizol extraction/lithium chloride precipitation. Total RNA from all experiments was quantified and checked for purity by NanoDrop (Thermo Scientific), and 500 ng was used to prepare 20 ll of cDNA with an iScript cDNA Synthesis Kit (170-8891; Bio-Rad) according to manufacturer's directions. Real-time PCR was performed in triplicate using 1 ll of DNA template, 10 ll of ABI SYBR green PCR master-mix (4367659; Applied Biosystems), and 0.5 lM custom primers (Invitrogen) for Taf4a, Taf4b, Esr1, Esr2, or Actb in a 20-ll reaction in an ABI 7900 Real Time PCR machine (Applied Biosystems). Data were analyzed by the DDCt method, and relative expression levels were normalized to Actb (b-actin) to correct for equivalent total RNA levels. Error bars represent the SD of the fold-change over vehicle, placebo, or wild type of normalized gene expression values for all ovaries in one treatment group or time point. P values were determined by twotailed unpaired Student t-test.
Primer sequences are as follows:
Antibodies and Western Blot Analysis
Whole ovaries or cell pellets were dounce homogenized, and soluble protein was extracted in low-salt protein extraction buffer (0.2 M potassium chloride, 0.1 M Tris [pH 8.0], 0.2 mM EDTA, 0.1% NP40, 10% glycerol, and 1 mM PMSF). Protein concentrations were determined by Bradford assay (500-0006; Bio-Rad). Western blot analysis was performed by loading equal amounts of protein boiled with dithiothreitol and loading buffer into a 7.5% polyacrylamide gel. Protein was transferred to a nitrocellulose membrane at 0.25 A for 1 h. Membranes were blocked in 5% milk in Tris-buffered saline with 0.05% Tween 20 (TBS-T) for 1 h at room temperature, incubated in primary antibody in 1% milk in TBS-T overnight at 48C, and then in secondary antibody in 1% milk in TBS-T for 1 h at room temperature, with TBS-T washes in between. The Amersham ECL Plus Western Blot Detection System (RPN2132; GE Healthcare) was used for detection of horseradish peroxidase-tagged secondary antibodies. b-Tubulin or glyceraldehyde phosphate dehydrogenase (GAPDH) was used as a loading control. Antibodies and dilutions used are as follows: (1) mouse monoclonal anti-TAF II 135 (1:250; 612054; BD Transduction Laboratories); (2) polyclonal rabbit anti-mouse TAF4B (1:250; raised against amino acids 1-98 [N-terminus/coactivator domain] of mouse TAF4B, affinity purified, detects a band at 105 kDa, which is not detected in protein extract from Taf4b-null mice, and labels granulosa cells in wild-type mice, but not Taf4b-null mice [27, 28] ); (3) mouse anti-FLAG M2 (1:3000; F3165; Sigma); (4) rabbit anti-b-tubulin (1:250; 2013-06; Thermo Scientific); and (5) mouse monoclonal anti-GAPDH (1:5000; AM4300; Applied Biosystems).
Immunohistochemistry
Ovaries and oviducts of 4-wk-old C57/Bl6 mice were dissected, formalin fixed for 24 h, paraffin embedded, and sectioned at 5 lm. Sections were deparaffinized and rehydrated, and antigen unmasking was performed by placing slides in 1:100 Antigen Unmasking Buffer (H-3300; Vector Laboratories) in deionized water in a steam cooker for 20 min. Slides were cooled on the bench for 20 min, and then sections were permeabilized in 0.1% Triton and 0.1% sodium citrate for 15 min. Endogenous peroxide activity was blocked by placing slides in 3% hydrogen peroxide in methanol for 30 min.
Avidin-biotin blocking was performed using an Avidin-Biotin Blocking Kit (SP-2001; Vector Laboratories) according to manufacturer's directions. Sections were blocked using ready-to-use 2.5% horse serum (S-2012; Vector Laboratories) and were incubated overnight at 48C with rabbit anti-TAF4B antibody [27, 28] at 1:100 dilution or with horse serum alone. The following day, sections were rinsed with PBS and incubated with biotinylated anti-rabbit IgG antibodies (BA-1100; Vector Laboratories), for 1 h at room temperature. After PBS wash, sections were incubated in ready-to-use ABC Vectastain reagent (PK-7100; Vector Laboratories) for 45 min and washed with PBS. Sections were then developed in Vector NovaRED substrate (SK-4800; Vector Laboratories) and counterstained briefly with methyl green. Slides were cleared with isopropyl alcohol and successive Citrisolv Hybrid (04-355-121; Fisher Scientific) incubations and coverslipped using Cytoseal 60 mounting media (8310-16; Richard-Allan Scientific). Sections were imaged at 203 or 403 magnification with a ScanScope CS imaging system (Aperio).
RESULTS
Ovarian Taf4b mRNA and TAF4B Protein Expression in Estrogen-Treated Mice
We previously observed that Taf4b-null granulosa cells fail to proliferate in response to eCG or 17b-estradiol treatment [28] . We predicted that if TAF4B is necessary for proliferation of granulosa cells then TAF4B expression may be upregulated in the ovary during these proliferative responses. To this end, 4-wk-old C57Bl/6 female mice were injected s.c. with 0.25, 0.5, 1.0, or 2.0 mg of 17b-estradiol, once daily for 3 days. Compared with control mice receiving corn oil alone, Taf4b mRNA levels were increased in a dose-dependent manner in response to estradiol. Ovaries from mice exposed to 0.25 mg/ day of estradiol demonstrated a 1.2-fold increase in Taf4b mRNA; 0.5 mg/day resulted in a 1.7-fold increase in Taf4b mRNA (P ¼ 0.011), 1.0 mg/day resulted in a 2.0-fold increase (P ¼ 4.5 3 10 À4 ), and 2.0 mg/day resulted in a 2.15-fold increase (P ¼ 8.7 3 10 À4 ). Conversely, Taf4a mRNA expression remained relatively constant between treated and control ovaries, indicating a specific response of Taf4b to estrogen (Fig. 1A) . Similar results were obtained with treatment with the synthetic estrogen DES (data not shown). In order to compare the effects of 17b-estradiol with DES exposure, we treated mice with 17b-estradiol or DES. As a negative control, the inactive stereoisomer of 17b-estradiol, 17a-estradiol, was used. Mice were treated with 1.0 mg of 17a-estradiol, 17b-estradiol, DES, or vehicle alone, once daily for 3 days. The dose of 1.0 mg/day administered s.c. is sufficient to induce follicular growth and was selected in order to observe the effects of exogenous estrogen on Taf4b expression. Ovaries exposed to 17a-estradiol displayed no significant increase in Taf4b, while ovaries from mice exposed to 17b-estradiol displayed a 2.85-fold increase in Taf4b mRNA (P ¼ 2.6 3 10 À5 ), and ovaries from mice exposed to DES displayed a 2.5-fold increase in Taf4b (P ¼ 2.9 3 10 À5 ). Again, levels of Taf4a remained unchanged with all forms of estrogen exposure, demonstrating a specific effect on Taf4b expression (Fig. 1B) . Although DES is thought to have greater potency than 17b-estradiol [35] in regard to upregulation of Taf4b, we observed a similar potency. Therefore, these compounds were used interchangeably throughout the remainder of the studies.
In order to determine whether these findings were recapitulated at the protein level and to distinguish whether the upregulation was the consequence of an increased number of cells expressing Taf4b or an increased level of expression in the granulosa cells after estrogen stimulation, we purified granulosa cells of DES-treated or vehicle-treated ovaries and examined mRNA and protein expression in samples consisting of cells pooled from three mice per sample. We observed a 2.66-fold increase in Taf4b mRNA expression in DES-treated granulosa cells (P ¼ 0.001) (Fig. 2A ). An increase in TAF4B ESTROGEN RESPONSIVENESS OF TAF4B IN THE OVARY protein expression was also evident in DES-treated granulosa cell extracts (Fig. 2B ). When mice were injected i.p. with 5 IU of eCG, no significant changes were detected in either Taf4a or Taf4b mRNA expression or TAF4B protein expression in purified granulosa cells pooled from five mice (Supplemental Fig. S1 , A and B, available online at www.biolreprod.org). However, when the expression levels of Taf4b were examined in whole ovaries from six individual mice, a small but statistically significant change was noted, which may be attributed to slightly increased estradiol levels following eCG treatment (Supplemental Fig. S1C ). The modest upregulation is likely due to the small effect that 5 IU of eCG has on intraovarian and serum estradiol levels at 24 h [36] . To elucidate whether the response to estrogen was restricted to the ovary, we examined levels of Taf4b in uterine horns and mammary glands from mice treated with 1.0 mg of DES, once daily for 3 days. In contrast to the upregulation observed in granulosa cells of the ovary, Taf4b levels were not increased by estrogen in either uterine horns or mammary glands ( Fig. 2A) .
Time Course of Taf4b Upregulation in Response to Estrogen Stimulation
To gain a better understanding of the dynamics of Taf4b upregulation by estrogen, we performed a time course study by treating 4-wk-old C57Bl/6 mice i.p. with a single dose of 1.0 mg/kg of DES or with vehicle alone. This dose was selected for i.p. injection due to the direct and immediate exposure of the ovary to the compound, which was more suitable for a time course analysis. Quantitative RT-PCR revealed that Taf4b whole-ovary mRNA levels trended toward increased expression as early as 1 h after treatment. Levels peaked between 3 h (2.08-fold increase, P ¼ 0.001) and 6 h (3.3-fold increase, P ¼ 0.03). The larger error bar at 6 h is due to one outlier mouse with higher expression in the treated ovaries. By 24 h after injection, Taf4b levels returned to normal. Taf4a levels remained steady throughout the time course (Fig. 3) . Furthermore, we observed a parallel time course of upregulation for the estrogen-response gene c-Myc (data not shown), which has been demonstrated to be upregulated by estrogen via ER interactions with a promoter region containing an ERE half-site and an activating protein (AP-1) site [37] . These data show that the upregulation of Taf4b by estrogen occurs within hours, but not immediately, after estrogen stimulation and are consistent with a genomic response to estrogen [37, 38] .
Taf4b Upregulation via Nuclear ERs
Due to the time frame of Taf4b response to estrogen, we hypothesized that the response occurs via genomic estrogen- (Fig. 4A) . In comparison, Taf4a levels were unchanged by these treatments.
To determine whether this effect is mediated by ERa, ERb, or both, mice were injected i.p. with 20 mg/kg of the ERa agonist PPT or the ERb agonist DPN and killed 4 h later. Taf4b mRNA levels in the whole ovary were increased significantly by 1.9-fold (P ¼ 0.0013) with DPN administration (Fig. 4B) . We also noted a smaller but statistically significant 1.5-fold increase in Taf4b levels with PPT treatment (P ¼ 0.044), suggesting that ERa may also be able to stimulate Taf4b expression (Fig. 4B) .
To address the effect of exogenous ERs on TAF4B levels, we overexpressed ERb in a mouse granulosa cancer cell line, NT-1. Quantitative RT-PCR revealed a 2.59-fold increase in Taf4b levels with overexpression of ERb (P ¼ 1.9 3 10 À5 ) and no change in Taf4a levels (Fig. 5A) . Western blot analysis confirmed expression of 33FLAG-ERb and corroborated an increase in TAF4B protein expression in the samples overexpressing ERb. Some fluctuation in TAF4A protein expression was observed, but levels did not correlate with exogenous expression of ERb (Fig. 5B) .
In order to further validate the regulation of Taf4b by ERs, we analyzed mRNA expression of Taf4b in whole ovaries of ER-knockout mice (Ex3aERKO, Ex3bERKO, and Ex3-bERKO) [32] [33] [34] and control ovaries. Ovaries from 3-mo-old female mice were utilized to avoid any confounding issues due to the appearance of seminiferous tubulelike structures that occurs in Ex3abERKO mice around 7 mo of age [39] and the natural decline in TAF4B levels we observe in aged mice [27] . Taf4b mRNA levels were reduced by 2.69-fold (P ¼ 0.00078) in Ex3abERKO ovaries, which are deficient for both ERa and ERb, compared with age-matched control ovaries. Taf4b expression was not significantly changed in Ex3aERKO or Ex3bERKO ovaries, suggesting that in the absence of one receptor the other is able to maintain Taf4b expression. This idea is supported by the 2.5-fold increase in Esr1 (ERa) mRNA levels in Ex3bERKO preovulatory granulosa cells, where ERa is normally expressed at low levels [33] . Taf4a levels were unchanged in all Ex3ERKO samples (Fig. 6 ).
Taf4b Expression in Estrogen-Supplemented Mouse Ovarian Tumors
Although the contribution of estrogen to ovarian tumorigenesis and cancer progression is not fully understood, disruption of hormonal signaling pathways may contribute to ovarian cancer, particularly because the ovary relies on the careful balance of estrogen-dependent pathways to regulate ovarian functions such as proliferation and atresia [3] . In order to determine whether upregulation of TAF4B occurs in the context of ovarian tumor progression, in particular during epithelial tumor progression, we compared Taf4a and Taf4b mRNA levels between mice exposed and not exposed to exogenous estrogen throughout ovarian tumor growth. The Results are shown as the fold-change over vehicle-treated mice. Error bars represent the SD of the fold-change value. *P , 0.05, **P , 0.005, and ***P , 0.0005. The asterisk over the bar for Taf4b-ICI/DES indicates significance compared with Taf4b-DES treated.
ESTROGEN RESPONSIVENESS OF TAF4B IN THE OVARY
SCID mice received a 60-day slow-release 17b-estradiol pellet or placebo pellet s.c. and concurrently with i.p. injection of ascites cells from tgCAG-LS-TAg mice, which develop ovarian tumors of epithelial cell origin by targeted ovarian surface epithelial expression of T antigen [12] . Tumors developed in all 10 transplanted mice, and mice exposed to exogenous estrogen had a significantly shorter median survival (32 vs. 77 days, P ¼ 4.5 3 10 À4 ). Total RNA was prepared from tumors removed from the SCID mice at end point, and quantitative RT-PCR was performed for detection of Taf4a and Taf4b. Taf4b mRNA was increased significantly in the estradiol-exposed tumors, with an average fold-change of 10.94 (P ¼ 0.0014). Taf4a levels remained constant in all tumors. Furthermore, Taf4b upregulation correlated with a 2.31-fold increase in Esr1 mRNA (ERa, P ¼ 0.034) and a 4.83-fold increase in Esr2 mRNA (ERb, P ¼ 0.032) in the estradiolexposed tumors (Fig. 7) .
The upregulation of Taf4b by estrogen in the context of ovarian cancer led us to ask whether TAF4B is expressed in normal OSE and in epithelial cells of the oviduct, which are now widely regarded as the cell of origin for a majority of human ovarian tumors [40] . Previously, we reported the highest expression of Taf4b in ovarian granulosa cells and oocytes [27] . For the first time to date, we show that surface epithelial cells of the ovary also express TAF4B (Supplemental Fig. S2, A and C) . Furthermore, all epithelial cells of the oviduct, including those at the fimbriated end, display expression of TAF4B (Supplemental Fig. S2, A and B) .
Together, these data demonstrate the likelihood that TAF4B is expressed in the cells of origin that give rise to the majority of ovarian cancers in women.
DISCUSSION
The data presented herein reveal TAF4B as a novel estrogen-response gene in the ovary and a candidate component of estrogen signaling that merits closer investigation in the context of infertility and ovarian cancer. We have previously identified TAF4B as an ovary-enriched subunit of the TFIID complex that is required in many aspects of murine fertility [26] [27] [28] . Presently, we describe the specific upregulation of TAF4B by estrogen in both the normal mouse ovary and ovarian tumors. The estrogen responsiveness of TAF4B is striking contrasted with the nonresponsiveness of its ubiquitously expressed paralog, TAF4A. Because TAF4B is a critical integrator of ovarian-specific transcription programs, its modulation by estrogen may partly explain how it evolved an essential role in female fertility. It is also significant to note reduced ovarian Taf4b expression when mice are treated with the ER antagonist ICI 182 780, as well as reduced expression in Ex3abERKO ovaries, indicating that basal levels of TAF4B are dependent upon ER expression and activation. Taf4b displays a significant increase in response to the ERb agonist DPN, and overexpression of ERb in NT-1 cells causes concomitant upregulation of Taf4b mRNA and TAF4B protein.
The modest upregulation of Taf4b by the ERa agonist PPT suggests the likelihood of the ability of ERa to regulate Taf4b expression as well. This is supported by the reduced expression in Ex3abERKO ovaries, but not in Ex3bERKO ovaries that contain elevated levels of ERa ectopically expressed in granulosa cells in the absence of ERb [33] . It is unknown whether ERb, like ERa in Ex3bERKO ovaries, is aberrantly expressed in Ex3aERKO ovaries. Thus, we conclude that Ex3aERKO ovaries are able to maintain TAF4B levels via endogenous ERb that is normally highly expressed in the granulosa cells. Because ERs can either homodimerize or heterodimerize to regulate target genes [19] , perhaps homodimerization is favored in the case of higher expression of one receptor over another. We speculate that ERa-dependent upregulation of Taf4b might occur in cell types in which ERb is not as highly expressed such as the surface epithelial cells of the ovary [41] . If this is the case, it is plausible that only a modest upregulation would be noted with PPT treatment due to the small percentage of the ovary that is composed of the OSE. In agreement with this hypothesis, OSE-derived mouse tumors have been shown to express high levels of ERa [12] , and the present study confirms significant upregulation of Taf4b in estradiol-treated tumors compared with control tumors. These tumors are heterogeneous and do contain a stromal component [12] , but the localization of TAF4B to the stromal versus epithelial compartment of these tumors is not yet known. Because we observe upregulation of both ERs in these tumors, it is possible that upregulation of TAF4B in these tumors occurs via ERa, ERb, or both. Future studies will determine the mechanisms by which TAF4B is upregulated in estrogensupplemented ovarian tumors.
Although the time frame of Taf4b upregulation and our modulations of ER expression and activity in vivo and in vitro support the notion that Taf4b upregulation occurs via nuclear ERs, we were unable to identify a perfect ERE in the human or mouse Taf4b promoters. However, nonconsensus EREs may in certain instances be able to confer estrogen responsiveness [42] . It is also possible that estrogen responsiveness may be achieved via alternate sequence combinations such as two ERE half-sites upstream of a specificity protein 1 (SP-1) site, as reported in the human progesterone receptor A promoter [43] , or an ERE-half site and an AP-1 site, as reported for C-MYC [37] . Alternatively, Taf4b upregulation may occur by way of nonclassical nuclear ER signaling whereby ERs interact with transcription factors that bind to non-ERE sites such as AP-1 or SP-1 sites [21] . These scenarios are plausible because we were able to identify putative AP-1, SP-1, and ERE half-sites within the Taf4b promoter (data not shown) and because the c-Myc gene, which is regulated in this fashion, exhibited a parallel pattern of upregulation to Taf4b. Last, we cannot eliminate the possibility of a convergence of genomic and nongenomic signaling in regulation of Taf4b expression because the typically nuclear ERs have been reported to be able to act at the membrane in some cases and because phosphorylation of mitogen-activated protein kinases, as occurs during nongenomic signaling, can also impact nuclear ER activity [21] . Studies that investigate these possibilities are under way.
These data raise the question of the biological importance of TAF4B regulation by estrogen. Evidence shows that TAF4B is present along with TAF4 (the human ortholog of mouse TAF4A) in a subset of purified human TFIID complexes and that complexes containing both TAF4B and TAF4 have slightly different conformations than TFIID complexes containing TAF4 alone [44] . Importantly, this conformational change translates to functional differences in core promoter selectivity that are enhanced in the presence of specific coactivators [44] . In this scenario, deregulated levels of TAF4B could lead to altered transcription of genes preferentially targeted by TFIID complexes containing TAF4B such as the proto-oncogene c-Jun. Besides c-Jun, a few putative TAF4B target genes have been identified in the ovary [27, 45] ; however, it is plausible that a much larger set of genes is deregulated following TAF4B upregulation or downregulation due to global transcriptional alterations in a cell containing TFIID complexes with different TAF4B-containing:TAF4-alone ratios. The multitude of defects observed in Taf4b-null mice and the variability in gene sets altered at diverse time points support this idea [26] [27] [28] 46] .
Another possible scenario exists whereby TAF4B may be involved in estrogen-dependent signaling. It has been shown that TAF4B can function as a coactivator for nuclear factor-jB in human 293 cells and thereby mediate activation of antiapoptotic genes in response to tumor necrosis factor a [47] . It is interesting to speculate whether TAF4B may have additional coactivator functions with ERs because ERs are known to regulate tissue-specific gene networks due to unique cellular compositions of coactivator proteins [20] . Future studies will elucidate if the absence of TAF4B affects downstream transcriptional responses to estrogen in the normal mouse ovary or if TAF4B interacts with ERs.
The upregulation of Taf4b by estrogen in ovarian tumors suggests that TAF4B-dependent transcription is activated during estrogen-supplemented tumor development and raises the possibility that TAF4B helps mediate the effects of estrogen on tumor latency and/or progression in these mice. Although TAF4B is likely primarily regulated by ERb in granulosa cells, it is possible that ERa assumes this role in epithelial ovarian tumors that frequently lose ERb expression [48] . It is also interesting to note the localization of TAF4B in epithelial cells of the ovary and oviduct, which are important in epithelial tumorigenesis, although the function of TAF4B in these cell types has not been characterized to date. On the other hand, TAF4B could potentially have a role in granulosa cell tumorigenesis because ERb is frequently highly expressed in these tumors [19] . Studies in tgCAG-LS-TAg-null and Taf4b-null mice will help us elucidate any potential function TAF4B has in ovarian tumorigenesis. In addition, the reduction of Taf4b expression by ICI 182 780, and in Ex3abERKO ovaries, is in agreement with the known fertility function of Taf4b because Ex3abERKO mice are infertile as well [34] . Because patients with POF exhibit reduced estradiol levels [5] , it is plausible this could impact TAF4B expression, which could potentially contribute to infertility in these patients. Further dissection of the connection between TAF4B and estrogen signaling in the ovary will broaden our understanding of normal ovarian biology and help us formulate hypotheses regarding these disease states.
In conclusion, we have described the novel ovarian-specific response of the TFIID subunit TAF4B to estrogens in the whole ovary, in purified granulosa cells of the ovary, and in ovarian tumors. The upregulation of Taf4b is unique in that   FIG. 7 . Expression of Taf4a, Taf4b, and ERs in tumors from SCID mice that received cultured tgCAG-LS-TAg ascites cells concurrently with a placebo or estradiol pellet. Real-time PCR quantification of Taf4a, Taf4b, Esr1, and Esr2 levels in tumors exposed to 17b-estradiol throughout tumor progression (n ¼ 6 placebo and n ¼ 4 estradiol). Results are shown as the fold-change over placebo-exposed tumors. Error bars represent the SD of the fold-change value. *P , 0.05 and **P , 0.005.
ESTROGEN RESPONSIVENESS OF TAF4B IN THE OVARY
levels of its paralog, Taf4a, are unchanged with estrogen treatments. Furthermore, Taf4b upregulation likely occurs via nuclear ER signaling because a pan-ER antagonist inhibited the response of Taf4b to DES, and ER agonists increased Taf4b expression. These results were corroborated by overexpression of ERb in a granulosa cancer cell line, which produced a concomitant increase in TAF4B levels. Last, the reduction of Taf4b expression by a pan-ER antagonist and in Ex3abERKO mice demonstrates that both nuclear ERs are able to regulate Taf4b expression and that basal levels of Taf4b are dependent upon ER activity. These results set the stage for further research into the mechanism and biological significance of the estrogen responsiveness of TAF4B, as well as the implications of this regulation for ovarian disease states.
